Suzhou Zelgen Biopharmaceuticals (SHA:688266) posted first-half attributable net profit of 640.0 million yuan, compared with loss of 72.8 million yuan the previous year.
Earnings per share stood at 2.42 yuan, versus loss per share of 0.28 yuan, according to a semi-annual report on the Shanghai bourse.
Operating revenue jumped 221% year over year to 1.21 billion yuan from 375.7 million yuan.
Shares of the pharmaceutical company fell 12% in recent trade.